In our opinion, patients with significant p53 and Ki-67 IHC reactivity should undergo strict surveillance, even in the absence of other high-risk features (such as extensive colitis, stricture, primary sclerosing cholangitis or family history of CRC). This evidence concerns the gene TP53 and sclerosing cholangitis.